No patient benefitted from National Policy for Rare Diseases scheme, BJP MP writes to Health Minister

In a tweet, the MP stated, "Last year, the govt assured financial assistance of Rs 50 lakh to every rare disease patient. So far, not a single patient has benefited from this scheme. 10 children have died waiting for treatment.

Published On 2023-01-10 05:45 GMT   |   Update On 2023-01-10 05:54 GMT

New Delhi: Criticizing the implementation of the health ministry scheme, 'National Policy for Rare Diseases, 2021', the BJP MP Varun Gandhi has said that no patient has so far benefitted from the scheme, which assures assistance of Rs 50 lakh to people with rare diseases, warning that it endangers the lives of 432 patients, mainly children below six years of age.In a tweet, the MP stated,...

Login or Register to read the full article

New Delhi: Criticizing the implementation of the health ministry scheme, 'National Policy for Rare Diseases, 2021', the BJP MP Varun Gandhi has said that no patient has so far benefitted from the scheme, which assures assistance of Rs 50 lakh to people with rare diseases, warning that it endangers the lives of 432 patients, mainly children below six years of age.

In a tweet, the MP stated, "Last year, the govt assured financial assistance of Rs 50 lakh to every rare disease patient. So far, not a single patient has benefited from this scheme. 10 children have died waiting for treatment.

Also Read:Delhi HC directs centre to release over Rs 5 Cr to fund clinical trials for rare diseases

He urged the Union Health Minister Mansukh Mandaviya to act immediately by clearing these payments. 

In a letter to Mandaviya, Gandhi noted that the ‘National Policy for Rare Diseases, 2021’ was launched by the Ministry of Health and Family Welfare on March 30, 2021, to save the lives of patients suffering from rare diseases.

According to an amendment made to this in May 2022, all groups of rare disease patients have assured financial assistance of Rs 50 lakh for treatment, he said.

However, he said in the letter, even after several months of the announcement, not a single patient has been able to reap the benefits of this scheme, “threatening the survival of 432 patients, mainly children below six years of age”.

Most of these children suffer from Lysosomal Storage Disorders (LSD) such as gaucher, pompe, MPS I, MPS II and fabry disease, he said.

According to the Ministry of Health and Family Welfare crowdfunding platform, around 208 Lysosomal Storage Disorder patients can immediately be put on therapy since the Drugs Controller General of India-approved treatments for most of these diseases have been available in India for many yeas, Gandhi said.

Despite several reminders from the ministry, he said, the 10 Centers of Excellence (CoEs) constituted under the policy are yet to seek financial assistance for patients with rare diseases. According to organisations committed to the cause of rare disease patients, more than half of the CoEs have not sent a single treatment request to the health ministry, he added.

“Over ten children have lost their lives while waiting for treatment. Therefore, I request that the treatment of these 208 children at the Centres of Excellence start immediately. I hope you will consider this matter seriously as any delay in this regard will result in the loss of lives of many more children,” he said.



Also Read:ICMR Calls For Proposal In Therapeutics for Inherited Rare Diseases, Apply now

Tags:    
Article Source : with inputs

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News